10,000+ stock pitches from top investors available on joinyellowbrick.com
BAKER BROS. ADVISORS LP 13F Holdings
Holdings from the most recent 13F from BAKER BROS. ADVISORS LP
Filed: 2023-02-14 (Q4 2022) | Holdings: 113 | Value: $16.7B | Filing Link
PREMIUM
Author Returns
Returns are calculated from when the filing is published and are weighted by the size of the holding.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Filing Returns
Returns are calculated from when the filing is published and are weighted by the size of the holding.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Holding Returns | |||||||
|---|---|---|---|---|---|---|---|
| Stock | Put/Call | Change | Holding Pct | Value | Current Return | 3M Return | 1Y Return |
| SGEN - Seagen Inc. | 36.21% | $6.0B | +42.19% | ||||
| INCY - Incyte Corporation | 17.44% | $2.9B | -17.65% | -16.20% | -25.35% | ||
| BGNE - BeiGene, Ltd. | 15.41% | $2.6B | +4.38% | +2.12% | -37.91% | ||
| BMRN - BioMarin Pharmaceutical Inc. | 4.74% | $788.6M | -46.53% | -12.36% | -18.69% | ||
| ACAD - ACADIA Pharmaceuticals Inc. | 4.01% | $667.4M | +13.59% | +16.48% | +32.60% | ||
| ASND - Ascendis Pharma A/S | Add 2% ($12.5M) | 3.63% | $605.1M | +47.03% | -12.79% | +32.91% | |
| MDGL - Madrigal Pharmaceuticals, Inc. | Add 3% ($13.3M) | 2.69% | $448.5M | +2.97% | +8.60% | -16.87% | |
| RYTM - Rhythm Pharmaceuticals, Inc. | Add 5% ($8.5M) | 1.11% | $185.0M | +126.90% | -37.51% | +86.72% | |
| BCRX - BioCryst Pharmaceuticals, Inc. | 0.88% | $145.9M | +4.27% | -14.94% | -45.30% | ||
| IMCR - Immunocore Holdings plc | 0.86% | $143.9M | -41.67% | -1.77% | +12.35% | ||
| AKRO - Akero Therapeutics, Inc. | 0.78% | $129.8M | +10.36% | +6.05% | -52.41% | ||
| REPL - Replimune Group, Inc. | Add 18% ($18.6M) | 0.75% | $124.5M | -62.98% | -22.75% | -68.43% | |
| KOD - Kodiak Sciences Inc. | 0.74% | $123.9M | -53.10% | -27.31% | -25.24% | ||
| HZNP - Horizon Therapeutics Public Ltd Co | 0.66% | $110.4M | +2.44% | ||||
| ARGX - argenx SE | 0.64% | $106.1M | +52.55% | +8.08% | +4.71% | ||
| ABCL - AbCellera Biologics Inc. | 0.64% | $105.9M | -79.60% | -39.60% | -46.67% | ||
| KYMR - Kymera Therapeutics, Inc. | 0.43% | $71.9M | -10.99% | -10.21% | +12.37% | ||
| KDNY - Chinook Therapeutics, Inc. | 0.40% | $66.4M | +0.47% | ||||
| TRDA - Entrada Therapeutics, Inc. | 0.40% | $65.8M | -40.90% | -0.47% | +16.80% | ||
| MRTX - Mirati Therapeutics, Inc. | 0.38% | $63.9M | +3.13% | ||||
| PRLD - Prelude Therapeutics Inc. | 0.37% | $61.1M | -83.77% | +21.61% | -36.26% | ||
| CERS - Cerus Corporation | 0.35% | $58.6M | -56.36% | -36.08% | -17.87% | ||
| AVTE - Aerovate Therapeutics, Inc. | 0.35% | $57.9M | -11.17% | -8.81% | |||
| IGMS - IGM Biosciences, Inc. | 0.32% | $53.7M | -94.58% | -41.19% | -34.27% | ||
| IMTX - Immatics N.V. | Add 17% ($6.6M) | 0.27% | $45.2M | -33.78% | +23.34% | +41.15% | |
| NRIX - Nurix Therapeutics, Inc. | 0.26% | $42.6M | -0.28% | +1.88% | -7.60% | ||
| KNSA - Kiniksa Pharmaceuticals, Ltd. | 0.25% | $41.9M | +104.03% | +7.01% | +50.41% | ||
| SWTX - SpringWorks Therapeutics, Inc. | New Purchase | 0.24% | $39.8M | +53.60% | +1.05% | +57.94% | |
| IDYA - IDEAYA Biosciences, Inc. | 0.18% | $30.3M | +11.43% | +21.29% | +160.17% | ||
| DNLI - Denali Therapeutics Inc. | New Purchase | 0.18% | $30.3M | -54.97% | +8.91% | -37.55% | |
| XENE - Xenon Pharmaceuticals Inc. | 0.18% | $29.6M | -26.81% | +5.89% | +23.52% | ||
| VERV - Verve Therapeutics, Inc. | 0.16% | $27.4M | -79.25% | -17.67% | -38.09% | ||
| DICE - DICE Therapeutics, Inc. | New Purchase | 0.16% | $26.9M | +18.77% | |||
| TVTX - Travere Therapeutics, Inc. | Reduce 63% $(43.6M) | 0.15% | $25.8M | -25.50% | -18.95% | -56.65% | |
| BCYC - Bicycle Therapeutics plc | 0.15% | $25.0M | -66.79% | -3.56% | -10.75% | ||
| ANAB - AnaptysBio, Inc. | New Purchase | 0.14% | $24.0M | -13.54% | -24.66% | -11.47% | |
| KRYS - Krystal Biotech, Inc. | Reduce 28% $(9.5M) | 0.14% | $24.0M | +69.14% | +20.92% | +52.25% | |
| DBVT - DBV Technologies S.A. | 0.13% | $22.4M | -37.69% | +66.42% | -36.16% | ||
| FGEN - FibroGen, Inc. | New Purchase | 0.13% | $22.0M | -98.82% | -27.41% | -91.16% | |
| RARE - Ultragenyx Pharmaceutical Inc. | 0.13% | $21.8M | -21.06% | +13.71% | +7.31% | ||
| HRTX - Heron Therapeutics, Inc. | 0.12% | $20.3M | -26.85% | -48.25% | +12.06% | ||
| TSVT - 2seventy bio, Inc. | 0.12% | $19.3M | -9.49% | -55.13% | |||
| N/A - Insmed Incorporated | Reduce 41% $(13.5M) | 0.12% | $19.2M | ||||
| PRME - Prime Medicine, Inc. | New Purchase | 0.11% | $19.1M | -94.14% | -35.92% | -61.25% | |
| BMEA - Biomea Fusion, Inc. | 0.11% | $17.7M | -86.21% | +225.29% | +66.19% | ||
| BLUE - bluebird bio, Inc. | New Purchase | 0.10% | $17.3M | -95.77% | -29.93% | -81.63% | |
| SPRY - ARS Pharmaceuticals, Inc. | New Purchase | 0.10% | $17.1M | +82.66% | -1.14% | -8.10% | |
| NVTA - Invitae Corporation | 0.09% | $15.6M | -36.68% | -99.08% | |||
| OPT - Opthea Limited | New Purchase | 0.09% | $14.4M | -30.44% | -45.04% | ||
| ADAP - Adaptimmune Therapeutics plc | New Purchase | 0.09% | $14.4M | -82.27% | -15.76% | -24.24% | |
| ALT - Altimmune, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| CCXI - ChemoCentryx, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| CINC - CinCor Pharma, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| DSGN - Design Therapeutics, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| FMTX - Forma Therapeutics Holdings, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| GBT - Global Blood Therapeutics, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| TIL - Instil Bio, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| RLMD - Relmada Therapeutics, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| VSTM - Verastem, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| VERU - Veru Inc. | Reduce 100% | 0.00% | $0.00 | ||||